Cancer of Kidney Clinical Trial
Official title:
Identification of Key Risk Factors Associated With Neoplastic Complications After Renal Transplantation in Nord-Pas de Calais, Normandy and Picardy Regions
Kidney transplantation is now the treatment of choice for end-stage renal disease (ESRD).
Between 2800 and 3000 kidney transplants are performed each year in France and more than 33
000 patients are living with a functioning graft.
Preventing allograft rejection requires the use of immunosuppressive therapy, the intensity
decreases as the distance from the day of transplantation. Unfortunately, treatment favors
certain complications, including infectious and neoplastic. These represent a major cause of
mortality in these patients. If the frequency of skin cancer is greatly increased in this
population, that of solid tumors remains a concern. Approximately 20% of patients develop
cancer after 10 years of graft , half non- skin cancers, the main risk factor is
immunosuppressive therapy .
The aim of the study is to evaluate, in a large population of patients treated in 4 regions (
the Nord-Pas de Calais, the Upper and Lower Normandy and Picardy) risk factors (in particular
the nature of the immunosuppressive treatment) of developing a neoplastic complication, skin
cancers and solid tumors, after renal transplantation.
A retrospective analysis of the previous 10 years, from 2002 to 2011 will be conducted. This
study will better understand the epidemiology of these complications but also allow to
identify risk factors associated, including demographic, environmental and related to
immunosuppressive therapy.
Thereafter, we hope to implement preventive measures or prospective studies, allowing us to
reduce the prevalence of this complication.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT02669914 -
MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
|
Phase 2 | |
| Recruiting |
NCT05179824 -
Tempus Priority Study: A Pan-tumor Observational Study
|
||
| Recruiting |
NCT03896958 -
The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
|
||
| Not yet recruiting |
NCT05241561 -
Cabo-POLARIS : A Trial to Evaluate Cabozantinib Among Haemodialysied Patients
|
Phase 2 | |
| Completed |
NCT00199888 -
Safety Study With the Antibody, cG250, and Isotope, 124-Iodine, to Diagnose Patients With Renal Masses.
|
Phase 1 | |
| Completed |
NCT05363072 -
A Study to Describe the Kidney Cancer Patient Population Treatment, and Results in the Hospital District of Southwest Finland.
|
||
| Withdrawn |
NCT04127318 -
Low-moderate Intensity Pedaling During Immunotherapy Administration
|
N/A | |
| Recruiting |
NCT03452774 -
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
|
||
| Recruiting |
NCT05732857 -
Valveless Trocar Versus Standard Trocar in Robot-assisted Complex Partial Nephrectomy
|
N/A | |
| Terminated |
NCT01931462 -
Microwave Coagulation in Partial Nephrectomy Protocol
|
N/A | |
| Recruiting |
NCT03133286 -
Radiotherapy Assessments During Intervention ANd Treatment (RADIANT)
|
||
| Completed |
NCT02145559 -
A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors
|
Phase 1 |